title: [Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].
abstract: OBJECTIVE
  To generate a human papillomavirus (HPV16) prophylactic and therapeutic vaccine candidate for cervical cancer.
  
  
  METHODS
  HPV16 major capsid protein L1 gene/minor capsid protein L2 gene and HPV16 early E6/E7 genes were inserted into a vaccinia virus expression vector. A strain of non-recombinant vaccinia virus containing the sequences was obtained through a homologous recombination and identified.
  
  
  RESULTS
  DNA hybridization confirmed that the HPV16L1/L2/E6/E7 genes were integrated into vaccinia virus DNA. Western Blot result showed that full-length L1/L2/E6/E7 proteins were co-expressed in CEF cells infected with the recombinant virus.
  
  
  CONCLUSIONS
  NTVJE6E7CKL1L2 could be taken as a candidate of prophylactic and therapeutic vaccine for HPV-associated tumors and their precancerous transformations.
authors.affiliation: Department of Gynecologic Oncology, The Affiliated Oncology Hospital, Guangxi Medical University, Nanning 530021, China. huangwei@csco.org.com
authors.forename: Wei
authors.initials: W
authors.lastname: Huang
authors.forename: Hou-wen
authors.initials: HW
authors.lastname: Tian
authors.forename: Jiao
authors.initials: J
authors.lastname: Ren
authors.forename: Jiang-tao
authors.initials: JT
authors.lastname: Fan
authors.forename: Li
authors.initials: L
authors.lastname: Zhao
authors.forename: Tao
authors.initials: T
authors.lastname: Bian
authors.forename: Zhen-hua
authors.initials: ZH
authors.lastname: Lu
authors.forename: Li
authors.initials: L
authors.lastname: Ruan
mesh_terms: D000818:Animals; D015153:Blotting, Western; D036022:Capsid Proteins / Q000235:genetics / Q000378:metabolism; D002478:Cells, Cultured; D002642:Chick Embryo; D003001:Cloning, Molecular; D005260:Female; D015870:Gene Expression; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D009856:Oncogene Proteins, Viral / Q000235:genetics* / Q000378:metabolism; D027383:Papillomaviridae / Q000235:genetics* / Q000276:immunology; D050725:Papillomavirus E7 Proteins; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D053918:Papillomavirus Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism; D014162:Transfection; D014412:Tumor Virus Infections / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D014616:Vaccinia virus / Q000235:genetics*; D014779:Virus Replication
chemical_list: D036022:Capsid Proteins; C068651:E6 protein, Human papillomavirus type 16; C063316:L2 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D053918:Papillomavirus Vaccines; D011993:Recombinant Fusion Proteins; D012097:Repressor Proteins; C059731:oncogene protein E7, Human papillomavirus type 16; C063317:L1 protein, Human papillomavirus type 16